Ovarian Neoplasms |
NCT02066883: Prognostic Potential Cell Surface Markers CD47 / CD27 / CD8 and Pim-kinase in Patients With Hematologic Malignancies or Solid Tumors |
|
|
| Recruiting | N/A | 150 | RoW | | Cancer Centre of Monoclonal Therapy, LLC | Solid Tumor, Ovarian Cancer, Non-small Cell Lung Cancer, Chronic Lymphocytic Leukemia, Burkitt's Lymphoma | 07/15 | 02/17 | | |
NCT02090127: Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient |
|
|
| No Longer Available | N/A | | US | ficlatuzumab, AV-299, SCH 900105 | AVEO Pharmaceuticals, Inc. | Mullerian Mixed Tumor of Ovary | | | | |
NCT01000259: Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer |
|
|
| Recruiting | N/A | 174 | US | Laboratory Biomarker Analysis | Gynecologic Oncology Group, National Cancer Institute (NCI) | Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer | 01/00 | | | |
NCT01445275: Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 |
|
|
| Withdrawn | N/A | 2605 | US | Evaluation of Cancer Risk Factors, cancer risk factors evaluation, Medical Chart Review, Chart Review, Study of Socioeconomic and Demographic Variables | Gynecologic Oncology Group, National Cancer Institute (NCI) | Fallopian Tube Carcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Ovarian Carcinoma, Primary Peritoneal Carcinoma | 01/16 | | | |